TRUDI: TDXD+Durva in HER2+/Low IBC
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Invasive Breast Cancer|Inflammatory Breast Cancer Stage III|HER2-positive Breast Cancer|HER2 Low Breast Adenocarcinoma|Breast Cancer
Interventions: DRUG: Trastuzumab deruxtecan|DRUG: Durvalumab
Sponsor: Filipa Lynce, MD
Collaborators: AstraZeneca|Daiichi Sankyo